Suppr超能文献

伽玛刀放射外科治疗颅神经细胞瘤。

Gamma knife radiosurgery for cranial neurocytomas.

机构信息

Department of Neurosurgery, Medical Faculty, Marmara University, Istanbul, Turkey.

出版信息

J Neurooncol. 2011 Dec;105(3):647-57. doi: 10.1007/s11060-011-0635-0. Epub 2011 Jul 6.

Abstract

Gamma-knife surgery may be an effective alternative for treatment of central neurocytomas owing to its relative safety compared with conventional radiotherapy. In this paper we present results of gamma-knife treatment (GKS) of residual or recurrent neurocytomas. Twenty-two patients (14 female, 8 male) with recurrent or residual neurocytomas who underwent GKS were included. Diagnosis was based on histological findings. The proliferative potential of the tumors was examined by immunostaining with MIB-1 antibody, which is specific for detection of Ki-67 antigen. Tumor volume was determined by using post-gadolinium magnetic resonance images. After GKS treatment, MR imaging was scheduled at three-month intervals in the first year, at six months intervals in the second year, and yearly thereafter. Histopathological diagnoses were: 18 cases of central neurocytomas, two liponeurocytomas, one cerebral neurocytoma and one cerebellar neurocytoma. The MIB1 labeling index (LI) varied from 0 to 5.7%. Marked reduction in tumor volume was seen in 15 patients. In six patients, the tumor volume remained unchanged, and progression was observed for one patient. No complications because of GKS were noted. Shrinking effect on tumor volume increased with increasing duration of follow-up. On the other hand, high MIB labeling index did not seem to have an effect on tumor response to GKS treatment. Findings of this study suggest that GKS is an effective and safe treatment alternative for residual or recurrent neurocytomas. However, its effectiveness should be confirmed with larger studies.

摘要

伽玛刀手术可能是治疗中枢神经细胞瘤的有效替代方法,因为与传统放疗相比,它相对安全。本文报告了伽玛刀治疗(GKS)残留或复发性神经细胞瘤的结果。22 例复发性或残留神经细胞瘤患者接受了 GKS 治疗。诊断基于组织学发现。肿瘤的增殖潜能通过免疫组化 MIB-1 抗体检测进行检查,MIB-1 抗体特异性检测 Ki-67 抗原。肿瘤体积通过使用钆后磁共振图像确定。GKS 治疗后,第一年每三个月进行一次 MRI 检查,第二年每六个月进行一次,此后每年进行一次。组织病理学诊断为:18 例中枢神经细胞瘤、2 例脂肪神经细胞瘤、1 例脑神经细胞瘤和 1 例小脑神经细胞瘤。MIB1 标记指数(LI)从 0 到 5.7%不等。15 例患者肿瘤体积明显缩小。6 例患者肿瘤体积保持不变,1 例患者病情进展。未观察到 GKS 引起的并发症。肿瘤体积的缩小效果随着随访时间的延长而增加。另一方面,高 MIB 标记指数似乎对 GKS 治疗的肿瘤反应没有影响。本研究结果表明,GKS 是治疗残留或复发性神经细胞瘤的有效且安全的替代方法。然而,其有效性需要通过更大的研究来证实。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验